Imatinib and hypophosphatemia: Case report and review of literature
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events reported included edema, nausea, diarrhea, myalgia or mu...
Main Authors: | Erdem Şen, İrem Öner, Özlem Ata |
---|---|
Format: | Article |
Language: | English |
Published: |
Turkiye Klinikleri
2017-07-01
|
Series: | Journal of Oncological Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336417300031 |
Similar Items
-
Sarcomas del estroma gastrointestinal tratados con Imatinib®: presentación de 2 casos Gastrointestinal stromal tumors treated with Imatinib®: report of 2 cases
by: Mayté Lima, et al.
Published: (2006-06-01) -
Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis
by: Ryota Niikura, et al.
Published: (2016-05-01) -
Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute
by: Hui-Hua Hsiao, et al.
Published: (2006-12-01) -
Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
by: Shen H, et al.
Published: (2019-12-01) -
Aggressive surgical resection following neoadjuvant imatinib therapy for advanced duodenal tumor with hepatic metastasis
by: Varun Madaan, et al.
Published: (2019-01-01)